These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
11. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
12. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049 [TBL] [Abstract][Full Text] [Related]
14. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Kanzawa T; Germano IM; Kondo Y; Ito H; Kyo S; Kondo S Br J Cancer; 2003 Sep; 89(5):922-9. PubMed ID: 12942127 [TBL] [Abstract][Full Text] [Related]
16. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995 [TBL] [Abstract][Full Text] [Related]
17. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433 [TBL] [Abstract][Full Text] [Related]
18. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171 [TBL] [Abstract][Full Text] [Related]